UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER
SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR
SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 000-54523

Pharmagen, Inc.
(Exact name of registrant as specified in its charter)
 
9337 Fraser Avenue
Silver Spring, MD 20910
(204) 898-8160
(Address, including zip code, and telephone number, including
area code, of registrant’s principal executive offices)

Common Stock, $0.001 par value
(Title of each class of securities covered by this Form)

None
(Titles of all other classes of securities for which a duty
to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)
x
Rule 12g-4(a)(2)
x
Rule 12h-3(b)(1)(i)
o
Rule 12h-3(b)(1)(ii)
o
Rule 15d-6
o

Approximate number of holders of record as of the certification or notice date: 208
 
 
 
 

Pursuant to the requirements of the Securities Exchange Act of 1934, Pharmagen, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
 
 
  Pharmagen, Inc.,
a Nevada corporation
 
     
Dated: August 6, 2014
/s/ Mackie Barch  
  By: Mackie Barch  
  Its: Vice-Chairman  
 
 
2
 
Pharmagen (CE) (USOTC:PHRX)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Pharmagen (CE)
Pharmagen (CE) (USOTC:PHRX)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Pharmagen (CE)